Drug recall · March 27, 2019
Losartan Potassium and Hydrochlorothiazide Tablets recall
Why: CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 90 count bottles, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. NDC 33342-0052-10
- Lots / codes
Lot BLM715A, Jul-19
- Quantity
- 9695 bottles
- Company
- Macleods Pharma Usa Inc, Plainsboro, NJ
- Distribution
- NJ, NY, FL
- Initiated
- February 21, 2019 · Voluntary: Firm initiated
- Classified
- March 21, 2019
- Reported
- March 27, 2019
- Ended
- September 28, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydrochlorothiazide / losartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.